[Retinopathy of prematurity].
This review summarizes the knowledge and highlights recent advances in clinical research of retinopathy of prematurity (ROP). This disease is still important, because improvements in neonatal intensive care during the last years have increased the survival of the most immature newborns, but did not diminish the ROP frequency. Ophthalmologic screening and, if applicable, laser treatment at the optimal time for advanced ROP prevents blindness in most cases. The history, classification and the modern concepts of ROP pathophysiology are described. The results of various multicenter treatment trials are summarized. The current German screening guidelines are discussed with the guidelines of other nations. The therapeutic treatment strategies and the treatment results are discussed. The ophthalmologic disorders of former preterm infants, as higher rates of amblyopia, strabismus, and refractive error, are mentioned. Possible future therapies, e. g. anti-angiogenic factors are discussed.
Jandeck
C
C
Universitätsaugenklinik Charité - Universitätsmedizin Berlin, Berlin. claudia.jandeck@charite.de
Kellner
U
U
Foerster
M H
MH
D000550:Amblyopia / Q000175:diagnosis / Q000517:prevention & control; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001766:Blindness / Q000517:prevention & control; D005858:Germany; D006801:Humans; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal; D017075:Laser Coagulation; D015997:Neonatal Screening; D012030:Refractive Errors / Q000175:diagnosis / Q000517:prevention & control; D012178:Retinopathy of Prematurity / Q000175:diagnosis* / Q000517:prevention & control / Q000601:surgery; D012307:Risk Factors; D013285:Strabismus / Q000175:diagnosis / Q000517:prevention & control; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors